test header

ASH

Hematology

Orlando

Poster

Golcadomide demonstrates potent antiproliferative activity in T-cell lymphoma via degradation of IKZF1 and IKZF3

Zhongying Mo, Evgenia Kalashnikova, Scott Wood, Lynda Groocock, Andy Christoforou, Minerva Tran, Yumi Nakayama, Ryan Galasso, Younguk Sun, Diana Jankeel, Michael Angelo, Neil Bence, Antonia Lopez-Girona

Poster

Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma

Theodoros P. Vassilakopoulos, Javier L. Munoz, Huiqiang Huang, Ichiro Kawashima, Sung Yong Oh, Wojciech Jurczak, Juan Bergua, Ou Bai, Alejandro Berkovits, Keshou Zhou, Marc S. Hoffmann, Jason R. Westin, Maria Bouzani, Michał Kwiatek, Tai-Chung Huang, Argyrios Gkasiamis, Arpankumar Patel, Floriane Boucaud, Adrien Petel, Serena Perna, Grzegorz S. Nowakowski

Poster

Golseek-4: A Phase 3, randomized study of golcadomide, a potential, first-in-class, oral CELMoD™ agent, plus rituximab versus Investigator’s choice in patients with Relapsed/Refractory follicular lymphoma who have received ≥1 line of systemic therapy

Eliza Hawkes, Clémentine Sarkozy, Yuqin Song, Muhit Ozcan, Franck Morschhauser, Alex Herrera, Alev Akyol, Parth Rao, Antonia Di Micco, Adrien Petel, Serena Perna, Charalambos Andreadis

Poster

IQGAP1 is a novel non-degraded substrate of CELMoDs and involved in trafficking of immune cells to the tumor microenvironment

Hsiling Chiu, Ari Salinger, Patrick Hagner, Pei-Hsuan Chen, Andy Christoforou, Antonia Lopez-Girona, Ashok Dongre y Anita Gandhi

Poster

Outcomes of relapsed or refractory mature T/NK-cell lymphomas in the era of novel agents: A nationwide observational study in Japan

Hideki Uryu, Tsuyoshi Muta, Mitsumasa Watanabe, Kosei Matsue, Tatsuo Ichinohe, Atsushi Takahata, Masashi Sawa, Nobuyuki Takayama, Takafumi Yokota, Hiromichi Takahashi, Nobuhiko Yamauchi, Taku Tsukamoto, Kunihiro Tsukasaki, Motoaki Shiratsuchi, Kentaro Ido, Yasushi Takamatsu, Kisato Nosaka, Tadakazu Kondo, Tomoko Narita, Junichiro Yuda, Masaki Hayashi, Ryosuke Naka, Hiroaki Fujimori, Yuichi Baba, Mitsufumi Nishio, Kenji Ishitsuka, Koji Izutsu

Poster

BMS-986458, a first-in-class, highly selective, and potent ligand-directed degrader (LDD) of B-cell lymphoma 6 (BCL6) combined with T-cell engagers (TCEs) demonstrates preclinical synergistic antitumor efficacy for the treatment of B-cell non-Hodgkin lymphoma (NHL)

Gauri Deb, Alicia Benitez Rondan, Kelven Burnett, Hugo Olmedo, Pako Lopez Acosta, Ana Isabel Moreno Bernal, Steven Nguyen, Paola Castiglioni, Suzanne Coberly, Carla Guarinos, Lynda Groocock, Rama Krishna Narla, Antonia Lopez-Girona, Soraya Carrancio, Neil Bence

Oral

Safety and Efficacy of Elranatamab in Combination with Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Phase 1b MagnetisMM-30 Trial

Attaya Suvannasankha, Jonathan L. Kaufman, Ashraf Badros, Michel Pavic, Hock-Choong Lai, Muhammad S Raza, Parth S Shah, Patrick Y. Muller, Jorge Acosta, Margaret Hoyle, Erik R Vandendries, Jay Cheng, Alexander Lesokhin

Poster

Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial

Anna Sureda Balarí, Abdullah M. Khan, Albert Oriol, Mercedes Gironella Mesa, Faiz Anwer, Cristina Encinas, Brea Lipe, Paula Rodríguez-Otero, Ping Chen, Hongxia Lin, Kexin Jin, Thomas Solomon, Lilia Taningco, Olumoroti Aina, Paulo Maciag, Sagar Lonial

Poster

Longitudinal Analysis of MRD Negativity and Immune Dynamics in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated with Iberdomide, Daratumumab, and Dexamethasone from the CC-220-MM-001 Trial

Danny Jeyaraju, Sanhita Sengupta, Paulo Maciag, Anna Sureda Balari, Niels W.C.J. van de Donk, Sagar Lonial, Anita K. Gandhi, Michael Amatangelo

Poster

Real-world outcomes in relapsed/refractory multiple myeloma: Retreatment versus no retreatment with an anti-CD38 monoclonal antibody in the 2L and 3L in patients from the Flatiron Health database

Maria Nieto, Katie Gravagna, Jiaqi Fang, Yu-Hsuan Shih, Christian Gentili, Gabriela Hernandez-Rivera, Ying Qiu, Paulo Maciag

Poster

Reasons for Treatment Discontinuation in Multiple Myeloma: Insights from the PREAMBLE Registry

Ravi Vij, Mark Fiala, David Cella, Brian G.M. Durie, David J. Kuter, Claudio Cerchione, Kamaraj Karunanithi, Jing Bo Li, Amanda Crosbie, Gabriela Hernandez-Rivera, Antoine Tinel, Thomas S. Marshall, Meghan Podolsky, Karthik Ramasamy

Poster

Pharmacodynamic activity and clinical benefits of mezigdomide in high-risk biomarker subgroups from the CC-92480-MM-001 study

Tracy T. Chow, Nicholas Stong, Keyur Desai, Saleh Tamim, Chad C. Bjorklund, Joseph T. Hadala, Cynthia Donahue, Phillip Koo, Erica Petrlik, Jessica Katz, Anita K. Gandhi, Suzanne Trudel, Nizar J. Bahlis, Paul G. Richardson, Michael Amatangelo

Poster

Selinexor, mezigdomide, and dexamethasone in patients with relapsed/refractory multiple myeloma who relapsed or are ineligible for T-cell redirecting therapy: STOMP Phase 1 results

Clifton Mo, Cristina Gasparetto, Cristiana Costa, Andrew J. Cowan, Tomer Mark, Yi Chai, Trinayan Kashyap, Jessica Katz, Michael Amatangelo, Paul G. Richardson

Poster

Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with Relapsed/Refractory multiple myeloma (RRMM)

Susan Bal, Luciano J. Costa, Nizar J. Bahlis, Myo Htut, Omar Nadeem, Krina Patel, Scott Solomon, Jaclyn Davis, Ziyan Guo, Kevin Hsu, Hongxiang Hu, Krishna R. Juluri, Jessica Katz, Timothy Pulham, Safi yyah Ziyad, Sham Mailankody

Poster

EZH2 Inhibition Synergizes with Aiolos/Ikaros Degradation via Coordinated Chromatin Remodeling and FoxO Activation in Multiple Myeloma

Ting-Hsiang Huang, Chih-Chao Hsu, Junfei Zhao, Anita K. Gandhi, Patrick R. Hagner

Poster

Shared Immune Features Correspond to High-risk Multiple Myeloma across multiple human subtypes and murine model

Junia Vieirados Santos, Fnu Nabuqi, Alison S. Park, Alessia D'Anna, Tarek Mouhieddine, Kiana Chen, Erik Guillen, Roshan Mathews, Gregoire Lauvau, Jing Zhang, Katerina Kappes, Rudra Prasad Dutta, Julie Fortier, Chad Bjorklund, Michael Amatangelo, Anita Gandhi, Zhihong Chen, Seunghee Kim-Schulze, Michael Slade, Udo Oppermann, Rena Feinman, Santiago Thibaud, Joshua Richter, Shambavi Richard, Cesar Rodriguez Valdes, Adriana Rossi, Hearn Cho, Fotios Asimakopoulos, David Siegel, Ravi Vij, Sundar Jagannath, Samir Parekh, David Fooksman, Alessandro Laganà

Poster

BMS-986397, a first-in-class casein kinase 1α (CK1α) degrader in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): A phase 1 dose escalation study

Courtney DiNardo, Eduardo Rodríguez-Arbolí, Jordi Esteve, Olga Salamero, Andrew M. Brunner, Maria Calbacho, Daniel J. DeAngelo, Noelia Purroy, Josiana Limones, Carmen Jimenez, Hongxiang Hu, Griff McTume, Maria Dolores Jimenez, Javier Estrada, Yili Qian, Soraya Carrancio, Thomas Prebet, Timothy B. Campbell, Michael Pourdehnad, Geoffrey L. Uy

Poster

Predictive biomarkers of luspatercept and erythropoiesis-stimulating agent (ESA) hematological response and overall survival (OS) in patients with lower-risk myelodysplastic syndromes (LR-MDS) in the COMMANDS trial

Guillermo Garcia-Manero, Manuel Ugidos, Maroof Hasan, Matthew E. Stokes, Matteo Giovanni Della Porta, Amer M. Zeidan, Valeria Santini, Uwe Platzbecker, Rami S. Komrokji, Dimana Miteva, Veronika Pozharskaya, Anita K. Gandhi, Daniel L. Menezes, Rajasekhar N.V.S. Suragani

Poster

Real-world hemoglobin (Hb) outcomes of patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving first-line (1L) luspatercept or 1L erythropoiesis-stimulating agents (ESAs) in the US

Idoroenyi Amanam, Chidera Agu, Siddhi Korgaonkar, Abigail Hitchens, Samantha Slaff, Svetlana Gavrilov, Derek Tang, Rohan C. Parikh, Keith L. Davis, I-Hsuan Su

Poster

Real-world treatment patterns and outcomes of first-line luspatercept in patients with myelodysplastic syndromes in the United States

Mikkael A. Sekeres, Ahmed Hnoosh, Aylin Yucel, Dimana Miteva, Tracy Krimmel, Samantha Slaff, Derek Tang, Min Che, Yelina Wang

Poster

Treatment Patterns and Clinical Outcomes in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated With First-Line Luspatercept: Findings from a Medical Record Review in France and Germany

Christophe Willekens, Ahmed Hnoosh, Aylin Yucel, Dimana Miteva, Oliver Leismann, Ravi K. Goyal, Elizabeth Esterberg, Maria I. Jimenez, Ulrich Germing

Poster

A retrospective study to assess real-world treatment patterns and outcomes in luspatercept-treated patients with myelofibrosis-associated anemia who required red blood cell transfusion in the United States

Gabriela Hobbs, Ying Liu, Fabián Sanabria, Shalon Jones, Yeran Li

Poster

A Phase 2 Study of luspatercept in adults and adolescents with α-thalassemia: findings from the dose confirmation cohort in adolescents

Yongrong Lai, Meng-Yao Lu, Ying Zhao, Antonis Kattamis, Gian Luca Forni, Kitty Formentin, Pablo Gurman, Mingzhao Gao, Loyse Felber Medlin, Patricia Martin-Regueira, Vincent Jaquet, Vip Viprakasit

Poster

Impact of long-term luspatercept treatment on iron parameters in patients with transfusion-dependent and non-transfusion-dependent β-thalassemia: Results from the phase 3b long-term follow-up study

Ali T. Taher, Khaled M. Musallam, Maria Domenica Cappellini, Maria Dimopoulou, Antonis Kattamis, Silverio Perrotta, Paolo Ricchi, Manuela Balocco, Patricia Martin-Regueira, Loyse Felber Medlin, George Zhang, Veronika Pozharskaya, John B. Porter

Poster

Revisiting Erythroid Response in the Phase 3 BELIEVE Trial of Luspatercept in Patients with Transfusion-dependent β-Thalassemia Using Real-World Criteria

Khaled M. Musallam, Maria Domenica Cappellini, Antonis Kattamis, Kevin H. M. Kuo, Sujit Sheth, Patricia Martin-Regueira, Loyse Felber Medlin, George Zhang, Christopher Westcott, Ali T. Taher

Oral

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results

Marc S. Hoffmann, Julio Chavez, Jason R. Westin, Judit Mészáros Jørgensen, Javier Munoz, Cecilia Carpio Segura, Guilherme Fleury Perini, Emmanuel Bachy, Victoria Campbell, Caroline Riley, Franck Morschhauser, Daniel Morillo, Alev Akyol, Berengere de Moucheron, Michael Pourdehnad, Akshay Sudhindra, Soraya Carrancio, Jessica Voetsch, Gang Yang, Serena Perna, Jean-Marie Michot

Oral

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results

Julio Chavez, Jason R. Westin, Javier L. Munoz, Emmanuel Bachy, Judit Mészáros Jørgensen, Guilherme Fleury Perini, Daniel Morillo, Abel Costa, Parth Rao, Berengere de Moucheron, Gang Yang, Soraya Carrancio, Akshay Sudhindra, Michael Pourdehnad, Jessica Voetsch, Serena Perna, Jean-Marie Michot

Oral

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy Results

Grzegorz Nowakowski, Marc Hoffmann, Javier Munoz, Jason Westin, Alejandro Martín García-Sancho, Michał Kwiatek, Wojciech Jurczak, Maria Bouzani, Muhamad Alhaj Moustafa, Akshay Sudhindra, Argyrios Gkasiamis, Arpankumar Patel, Floriane Boucaud, Serena Perna, Theodoros Vassilakopoulos

Oral

BMS-986458, a first-in-class, bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Updated results from the phase 1 dose escalation study

Franck Morschhauser, David Qualls, Jennifer Lue, Anastasios Stathis, Marcel Nijland, Avyakta Kallam, Jörg Bittenbring, Guillaume Cartron, Noémie Lang, Marjolein van der Poel, Loïc Ysebaert, Vladan Vučinić, Alejandro Martin García-Sancho, Antonio Rueda Dominguez, Noelia Purroy, Berengere de Moucheron, Xiaosong Li, Carla Guarinos, Joseph Burnett, Alicia Benítez Rondán, Michael Pourdehnad, Jessica Voetsch, Diego Sobradillo, Jean-Marie Michot

Oral

Mezigdomide overcomes CRBN mutations emerging post IMiD Therapy

Edmond R. Watson, Chad C. Bjorklund, Nicholas Stong, Scott Hollingsworth, Olivia Pierce, Yilin Meng, Veerabahu Shanmugasundaram, Ting-Hsiang Huang, Vinidhra Sridharan, Tracy Chow, Michael Amatangelo, Patrick R. Hagner, Christoph W. Zapf and Anita K. Gandhi

Oral

Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk myelodysplastic syndromes (LR-MDS): a post hoc analysis from the COMMANDS trial

Valeria Santini, Matteo Giovanni Della Porta, Rami S. Komrokji, Veronika Pozharskaya, Thalia Farazi, Karen L. Keeperman, Yinzhi Lai, Dimana Miteva, Tracy Krimmel, Barkha Aggarwal, David Valcárcel, Pierre Fenaux, Jake Shortt, Uwe Platzbecker, Guillermo Garcia-Manero, Amer M. Zeidan

Oral

Luspatercept initiated at the maximum approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: interim analysis from MAXILUS

Amer M. Zeidan, Maria Diez Campelo, Valeria Santini, Rena Buckstein, Lionel Adès, Lea Sahagun, Gitanjali Das, Tatiana Zelinsky, Yinzhi Lai, Dimana Miteva, Ali McBride, Jose Alberto Nadal, Krzysztof Madry, David Valcarcel, Jose Miguel Torregrosa-Diaz, Dries Deeren, Sebastian Grosicki, Sangeetha Venugopal, Uwe Platzbecker, Luke Fletcher, Thomas Cluzeau, Matteo Giovanni Della Porta

Oral

Luspatercept reduces cardiac stress and improves cardiac function in a TET2-deficient mouse model with features of heart failure with preserved ejection fraction: Evidence from phase 3 COMMANDS trial and pre-clinical studies

Manuel Ugidos Guerrero,1 Sarita Nehra,2 Manoj Dokania,2 Gobinathan Rengarasu,2 Guillermo Garcia-Manero,3 Uwe Platzbecker,4 Anita K. Gandhi,1 Ching-Pin Chang,1 Ricardo Garcia,5 Jyoti Gulia,2 Rajasekhar N.V.S. Suragani,1 Maroof Hasan

Poster

Safety Data from the Non-Transfusion-Dependent Dose-Confirmation Cohort: a Phase 2a Study of Luspatercept in Pediatric Patients with β-Thalassemia

Vip Viprakasit, Jianpei Fang, Khaled M. Musallam, Yesim Aydinok, Thomas D. Coates, Olga Grabowska, Iryna Bluemmert, Wenlei Yu, Patricia Martin-Regueira, Nour Hawila, Giovanni Battista Ferrero

Oral

Mosunetuzumab or glofitamab in combination with golcadomide demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Charalambos Andreadis, Irit Avivi, Neta Goldschmidt, William Townsend, Mariana Bastos-Oreiro, Abraham Avigdor, Peter A. Riedell, Inna Tzoran, Toby A. Eyre, Pamela McKay, Pau Abrisquesta, Eva Gonzales Barca, Alejandro Martin Garcia-Sancho, Sara Galimberti, Antonia Kwan, James Relf, Wilfred Leung, Francis Mussai, Connie Y. Ma, Adrien Petel, Patrick Y. Muller, Xuefeng Hou, Christopher P. Fox

Oral

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

Sairah Ahmed, MD, Alejandro Martín García-Sancho, MD, PhD, Juan Luis Reguera Ortega, MD, Guillaume Cartron, MD, PhD, Aaron P. Rapoport, MD, Koji Izutsu, MD, PhD, Hervé Ghesquieres, MD, PhD, Hideki Goto, MD, PhD, Jeremy S. Abramson, MD, MMSc, Peter Borchmann, MD, Ulrich Jäger, MD, Manali Kamdar, MD, MBBS, Martin Dreyling, MD, Merav Bar, MD, Maria Strocchia, PharmD, PhD, Martina Raggi, PhD, Luciana Bueno, MD, Jessica Papuga, PhD, Silvia Colicino, PhD, Franck Morschhauser, MD, PhD

Poster

Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) for Second-Line Relapsed or Refractory Large B-Cell Lymphoma (LBCL): First Results from Long-term Follow-up of TRANSFORM

Manali Kamdar, MD, MBBS, Scott R. Solomon, MD, Jon Arnason, MD, Patrick B. Johnston, MD, PhD, Bertram Glass, MD, Veronika Bachanova, MD, PhD, Sami Ibrahimi, MD, Stephan Mielke, MD, Pim Mutsaers, MD, Francisco Hernandez-Ilizaliturri, MD, Koji Izutsu, MD, PhD, Franck Morschhauser, MD, PhD, Matthew Lunning, DO, Vincent Ribrag, MD, Yi Lin, MD, PhD, Rashmi Bhatnagar, MSc, Sandrine Montheard, MS, Jeremy S. Abramson, MD, MMSc

Poster

CAR T Cell Therapy Referral Patterns and Characteristics of Patients with Relapsed or Refractory (R/R) Large B Cell Lymphoma (LBCL) in the United States

Mazyar Shadman, MD, MPH, Fei Fei Liu, GDCE, MBA, Christine Fu, PhD, Michael Cantrell, PhD, Amit Goyal, MBA, Dwaipayan Mukherjee, MBA, Tara Graff, DO, MS

Poster

Outpatient (OP) Use of Lisocabtagene Maraleucel (lisocel) in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Real-World Data from the CIBMTR Registry

Krish Patel, MD, Matthew Lunning, DO, Konstantinos Sdrimas, MD, MBA, Minoo Battiwalla, MD, MS, Uttam Rao, MD, MBA, Yi Lin, MD, PhD, Sami Ibrahimi, MD, Jennifer L. Crombie, MD, Sairah Ahmed, MD, Iris Isufi, MD, Matthew Frigault, MD, David Bernasconi, MSc, Debasmita Roy, PhD, Marcelo C. Pasquini, MD, MS, Bradley D. Hunter, MD, MPH

Oral

Patient-reported Outcomes (PROs) with Lisocabtagene Maraleucel (liso-cel) in Patients with Third Line or Later (3L+) R/R MZL from the Phase 2 TRANSCEND FL Study

Reem Karmali, MD, Franck Morschhauser, MD, PhD, Koji Izutsu, MD, PhD, M. Lia Palomba, MD, Kirit Ardeshna, MD, MA, FRCP, Brian T. Hill, MD, PhD, Manali Kamdar, MD, MBBS, Stephen J. Schuster, MD, Antonio Pinto, MD, Saurabh Dahiya, MD, FACP, Merav Bar, MD, Maria Strocchia, PharmD, PhD, Jinender Kumar, MS, Jeremy S. Abramson, MD, MMSc

Poster

Real-World Evaluation of Health Care Resource Utilization, Clinical Effectiveness, and Safety of Lisocabtagene Maraleucel and Axicabtagene Ciloleucel Administered in the Outpatient (OP) Setting for R/R Large B-Cell Lymphoma (LBCL)

Sagar S. Patel, MD, Elise A. Chong, MD, Farah Toron, MSc, Fei Fei Liu, GDCE, MBA, Fangyi Gu, ScD, John H. Baird, MD, Sameh Gaballa, MD

Poster

Lisocabtagene Maraleucel (liso-cel) Demonstrates Superior Efficacy Across Inflammatory Risk Subgroups in Second-Line (2L) Large B-Cell Lymphoma (LBCL): A Retrospective Analysis of the TRANSFORM Study

Pradipta Ray, PhD, Abood Okal, PhD, Miguel-Angel Perales, MD, Sandeep S. Raj, MD, Roni Shouval, MD, PhD, Eniko Papp, PhD, Sahar Ansari, PhD, Krishna R. Juluri, MD, PhD, Amanda Przespolewski, DO, Debasmita Roy, PhD, Ethan G. Thompson, PhD, Julie A. Rytlewski, PhD, Eric Bleickardt, MD, Alessandro Crotta, MD, Timothy B. Campbell, MD, PhD, Leanne Peiser, DPhil

Poster

Karmma-3 subgroup analysis in older patients with Relapsed/Refractory multiple myeloma treated with idecabtagene vicleucel

Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Shinsuke Iida, Sophie Hello, Devender Dhanda, Prachi Ghodke, Martina Raggi, Roland Marion Gallois, Jaclyn Davis, Paula Rodriguez-Otero

Poster

Real-world outcomes in older adults with triple-class exposed multiple myeloma

Surbhi Sidana, Devender S. Dhanda, Sophie Hello, Jiaqi Fang, Gaurav Deshpande, Tao Gu, Luciano J. Costa

Poster

Real-world comparison of progression-free and overall survival between idecabtagene vicleucel (Ide-cel) and teclistamab in triple-class exposed relapsed/refractory multiple myeloma

Krina Patel, Jenny Chen, Devender Dhanda, Kevin Towle, Luciano Costa, Sikander Ailawadhi, Saad Usmani, Sridevi Rajeeve, Yi Lin, Sichen Liu, Shannon Cope, Surbhi Sidana

Poster

Assessment of pharmacodynamic efficacy biomarkers from a phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)

Safiyyah Ziyad, Kristina M. Jordahl, Hongxiang Hu, Ethan Thompson, Susan Bal, Myo Htut, Larry D. Anderson Jr, Tara Gregory, Luciano J. Costa, Omar Nadeem, Naomey Sarkis, Ziyan Guo, Wei-Ming Kao, Allison J. Kaeding, Shari Kaiser, Michael R. Burgess, Jesús G. Berdeja

Poster

Trial in progress: QUINTESSENTIAL—A phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)

Ciara L. Freeman, Nisha Joseph, Sarah M. Larson, Omar Nadeem, Nikhil Munshi, Shinsuke Iida, Sham Mailankody, Paola Neri, Tara Gregory, Julia Piasecki, Safiyyah Ziyad, Hongxiang Hu, Svenja Groeneveld, Sarah Johnston, Timothy Pulham, Sandy Wong, Jaclyn Davis, Susan Bal, Anupama Kumar, Krina Patel

Poster

Trial in progress: Quintessential-2—a Phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide

Eyal Lebel, Ahmed Abdulgawad, Stefania Bramanti, Gonzalo Garate, Phoebe Joy Ho, Mikko Keränen, Yael Cohen, Maja Vase, Amit Khot, Ida Bruun Kristensen, Richard LeBlanc, Cindy Lee, Wojciech Legiec, Hila Magen, María-Victoria Mateos, Danielle Oh, Ludek Pour, Natalia Schutz, Alexandros Spyridonidis, Katja Weisel, Jan Zaucha, Sarah Larson, Asya Varshavsky-Yanovsky, Kimberly Grazioli, Debashree Basudhar, Hongxiang Hu, Ya Meng, Lamis Eldjerou, Susan Bal, Simon Harrison, Rakesh Popat, Marc Raab, Paula Rodriguez-Otero

Poster

Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel, a GPRC5D-targeted chimeric antigen receptor T cell therapy, in combination with mezigdomide in patients with relapsed/refractory multiple myeloma.

Susan Bal, Luciano J. Costa, Nizar J. Bahlis, Myo Htut, Omar Nadeem, Krina Patel, Scott Solomon, Jaclyn Davis, Ziyan Guo, Kevin Hsu, Hongxiang Hu, Krishna R. Juluri, Jessica Katz, Timothy Pulham, Safi yyah Ziyad, Sham Mailankody

Poster

Journey of relapsed or refractory multiple myeloma (RRMM) after quadruple-class exposure (QCEx): Poor outcomes and high attrition

Doris K Hansen, MD; Lin Wang, MD, PhD; Fangyi Gu, PhD; Teofilia Acheampong, PhD; Meghan Podolsky, MS; Jaclyn Davis, MD; Krina K Patel, MD, MSc

Poster

Extended treatment-free hospitalization-free time and quality of life benefits with CAR T cell therapy in subgroups of patients with relapsed/refractory MM: Insights from the karmma-3 trial

Krina K. Patel, MD, MSc; Lin Wang, MD, PhD; Roland Marion-Gallois, MSc; Martina Raggi, PhD, MS; Sophie Hello, PharmD; Paula Rodriguez-Otero, MD, PhD

Oral

Impact of lenalidomide pre-apheresis on markers of T cell fitness and pharmacodynamic biomarkers in newly diagnosed multiple myeloma patients with suboptimal response to autologous stem cell transplantation

Hao Tang, Ethan Thompson, Dante B Descalzi-Montoya, Jensen Wong, Sonash Nayee, Yan Li, Dhong Hyun Lee, Shari Kaiser, Debashree Basudhar